Advertisement

Beyond patents and royalties: the perception and reality of doing business with the NIH

  • GIL BEN-MENACHEM
  • STEVEN M. FERGUSON
  • KRISHNA BALAKRISHNAN
Article
  • 114 Downloads

Young biotech startups can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur.

References

Copyright information

© Nature Publishing Group 2005

Authors and Affiliations

  • GIL BEN-MENACHEM
    • 1
  • STEVEN M. FERGUSON
    • 2
  • KRISHNA BALAKRISHNAN
    • 3
  1. 1.Gil Ben-Menachem is at Paramount Biosciences LLC, 124 Mount Auburn Street, Suite 200N, Cambridge, Massachusetts 02138, USA, gilben@paramountbio.com
  2. 2.Steven M. Ferguson is at the US National Institutes of Health Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, USA, fergusos@mail.nih.gov
  3. 3.Krishna Balakrishnan is at the US National Institutes of Health Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, USA, balki@nih.gov

Personalised recommendations